There is at least one example that I'm aware of where the company has come to an agreement with the funding agency that if the drug doesn't work in the first few cycles, no charge will be forwarded by the company to the agency. If the drug does work, then the agency will pay for the drug.
For these expensive cancer drugs, that may be one mechanism we should pursue.